Stock AnalizSavara Inc SVRA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Savara Inc (SVRA) is a healthcare company listed in the US with a market value of about $1.0B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -33%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $257000 | $0 | — | $0 | $400000 |
| Net income | -$119M | -$96M | -$55M | -$38M | -$43M | -$50M | -$78M | -$62M | -$30M | -$11M |
| Free cash flow | -$101M | -$89M | -$51M | -$35M | -$40M | -$40M | -$45M | -$39M | -$29M | -$8M |
| EPS (diluted) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 | $-0.84 | $-1.95 | $-1.85 | $-1.76 | $-5.62 |
| Net margin | — | — | — | — | — | -19305.5% | — | — | — | -2730.8% |
| ROIC | -53.0% | -41.1% | -28.4% | -22.9% | -19.2% | -42.7% | -48.4% | -46.6% | -19.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $11.06, 138% above the current price; targets range from $9.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.65 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Savara pay a dividend?
Not currently.
Is Savara a good stock to buy?
We do not give buy or sell advice. Savara scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.